Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy

NCT00801385 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: erlotinib hydrochloride
DRUG: sorafenib tosylate
GENETIC: DNA analysis
GENETIC: mutation analysis
GENETIC: polymerase chain reaction
GENETIC: protein analysis
GENETIC: protein expression analysis
OTHER: immunohistochemistry staining method
OTHER: laboratory biomarker analysis

Sponsor

Yonsei University